The one randomised trial that combined an incretin with supervised exercise

The most instructive trials in this area were run before anybody had heard of an incretin. In older adults with obesity randomised to diet, exercise, both or neither, the combination preserved physical function and attenuated the loss of bone and lean tissue that dieting alone produced. That population — older, heavier, losing weight fast — resembles a substantial share of the people now taking these drugs far more closely than the resistance-training cohorts from which most protein and training advice is drawn.

The one trial that combined an agonist with supervised exercise

A Danish randomised trial remains the only controlled test of the obvious question. After an eight-week low-energy diet producing approximately thirteen kilograms of weight loss, participants were randomised for one year to supervised exercise alone, liraglutide 3.0 mg alone, both combined, or placebo.¹ The combination arm achieved the largest weight reduction and, more relevantly here, the most favourable composition outcome: body fat percentage fell roughly twice as much in the combination group as in either single-intervention group, and the exercise arms preserved lean mass better than the drug-alone arm.

Three qualifications belong with that result. The exercise was supervised and substantial — two group sessions and two individual sessions weekly, with a vigorous-intensity target — which is not what most people mean by adding exercise. The agent was liraglutide at 3.0 mg daily, producing considerably less weight loss than the current agents, so whether the interaction scales to a twenty per cent reduction is unknown. And the trial began after weight had already been lost, so it is a maintenance study rather than an induction study.

With those stated, it is the best evidence in the field and it points in the direction the general advice already points.

What the older-adult trials found

The closest analogue to rapid weight loss in an older, heavier population predates this drug class entirely. In a randomised trial of adults aged sixty-five and over with obesity, assigned to diet, exercise, both or a control condition for a year, the combination produced the largest improvement in physical function, and the exercise component attenuated the loss of lean mass and of bone mineral density that diet alone caused.² Diet alone improved function too — carrying less mass helps — but by less, and at a measurable skeletal cost.

That trial is the template for how the question should be asked in this class: randomise the co-intervention, measure function as a primary endpoint, measure bone, and follow for long enough for the skeleton to respond. Its population, older and heavier and losing weight quickly, resembles a large share of current incretin users far more closely than the young resistance-trained cohorts from which most consumer advice descends.

The Journal cites it frequently for that reason and notes the obvious limitation: the weight loss achieved was roughly a tenth of body mass over a year, which is half or less of what the current agents produce. Whether the protective effect of training holds at twice the rate of loss is not established.

The prescription survives scrutiny; the reasoning often does not

Two claims are routinely bundled together and only one is well supported. The weaker claim is that resistance training during pharmacological weight loss builds or maintains muscle mass. In a substantial energy deficit, training generally attenuates the loss rather than preventing it, and net accrual is unusual outside of untrained beginners and the specific controlled-feeding conditions of the trials cited earlier. The stronger claim is that training preserves strength and physical function even where mass declines, which is consistently observed and is mechanistically sensible: a large part of early strength change is neural rather than structural.

The distinction has practical consequences. Somebody training hard, eating well, and watching their DXA appendicular lean mass fall by two kilograms across nine months has not failed at anything, and may be measurably stronger than at baseline. If the expectation set for them was mass preservation, they will read a normal outcome as a failure and may respond by eating more or training in ways that suit the metric rather than the goal.

The Journal reports the training recommendation and reports what it is expected to achieve, which is function first and mass second.

How the Journal reports a body-composition figure

Four things accompany every composition number in these pages. The instrument, because DXA, magnetic resonance, bioimpedance and creatine dilution are not interchangeable and the choice frequently determines the sign of the result. The sample size of the substudy rather than of the parent trial, because the parent trial size is irrelevant to the composition finding and quoting it is misleading. The definition used — total lean mass, lean soft tissue, appendicular lean mass or fat-free mass — because these differ by several kilograms in the same person. And whether the figure is a proportion of body mass or an absolute quantity.

Where a source omits any of the four, we say so rather than guessing, and where we have had to convert between definitions we show the conversion. This is more cumbersome than the alternative and it is the only way we have found to write about this subject without producing sentences that are technically true and practically misleading.

Readers who find a figure in these pages that lacks its instrument and its sample size have found an error, and the standards desk would like to hear about it at standards@compoundjournal.com.

What the testing services can and cannot tell you here

A category confusion arrives in the Journal postbag with some regularity, and it is worth addressing directly. The four independent testing services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — analyse the contents of a vial. They report chromatographic purity, identity by mass, sometimes peptide content, and in the case of the verification services, what they were able to establish about a supplier. None of them measures anything about a person.

A certificate stating 98.7 per cent purity for a batch supplied by WWB, SSA or KP is silent on that customer’s body composition, and a low-purity result does not explain a disappointing DXA scan. The two questions are answered by different instruments in different buildings, and conflating them produces a particular kind of dead end in which somebody spends several hundred pounds on analytical testing to investigate a clinical question.

The reverse confusion also occurs: a satisfactory laboratory panel or a favourable body-composition scan is offered as evidence that a vial contained what its label claimed. It is not evidence of that either. Compounds sold for research use only are not approved for human use, and nothing in this section should be read as advice about using them.

Readers should be sceptical of any body-composition figure quoted without its instrument, and sceptical of their own scans taken less than six months apart on different machines. The measurement error in this field is not a technicality; it is comparable in size to the effects being discussed, and it is the reason the same substudy tables support opposite conclusions in different hands.